Frontlight ResearchEarly access
CompletedNo phase
Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome
Key facts
- Who runs it
- University Hospital, Ioannina
- Where
- Greece1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 40 people enrolled
- Started
- 1 Jun 2023
- Ended
- 1 Feb 2026
- Type of study
- Observational, 3 groups
- Treatments tested
- Rituximab (MABTHERA® or RITUXAN®).
- Corticosteroids (CS)
- Record updated
- 14 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients with nephrotic syndrome and a biopsy-confirmed diagnosis of membranous nephropathy, primary focal segmental glomerulosclerosis, or minimal change disease
- Patients with membranous nephropathy and positive serum anti-PLA2R antibodies, in the absence of histological confirmation by renal biopsy
- Patients with a previously confirmed diagnosis of primary nephrotic syndrome who present with disease relapse requiring re-induction therapy
Who cannot take part
- Patients receiving, or who received within the preceding 6 months, immunomodulatory agents for an unrelated condition
- Patients with nephrotic syndrome in whom membranous nephropathy, primary FSGS, or MCD has not been confirmed by renal biopsy (and who do not meet Inclusion Criterion 2)
- Patients with secondary causes of nephrotic syndrome (malignancy, autoimmune disease, drug-induced, etc.)
- Patients with active malignancy
- Patients with severe heart failure (NYHA class IV) or hepatic failure
- Patients with active infection or inflammation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Immunophenotyping profiling of patients with primary MN, primary FSGS and MCD. Evaluation of these immune cell subsets as possible biomarkers to track response to treatment or disease relapse.
The 3 groups in the trial
- Primary Membranous Nephropathy
Patients with primary MN
Treatment: Rituximab (MABTHERA® or RITUXAN®).
- FSGS
Patients with primary focal segmental glomerulosclerosis
Treatment: Corticosteroids (CS)
- MCD
Patients with minimal change disease
Treatment: Corticosteroids (CS)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Immunophenotyping Profiling in Patients With Nephrotic Syndrome: Emphasis on the Diagnostic and Prognostic Value of Immune Cells in the Different Phenotypes of Nephrotic Syndrome.
- Record updated
- 14 July 2026